Ranbaxy Laboratories leads the BSE “HC” space

09 Apr 2012 Evaluate

Ranbaxy Laboratories is currently trading at Rs 497.10, up by 20.10 points or 4.21% from its previous closing of Rs 477.00 on the BSE.

The scrip opened at Rs 474.00 and has touched a high and low of Rs 497.40 and Rs 471.00 respectively. So far 198603 shares were traded on the counter.

The BSE group 'A' stock of face value Rs 5 has touched a 52 week high of Rs 570.00 on 02-Aug-2011 and a 52 week low of Rs 366.50 on 19-Dec-2011.

Last one week high and low of the scrip stood at Rs 497.75 and Rs 441.50 respectively. The current market cap of the company is Rs 20806.16 crore.

The promoters holding in the company stood at 63.68% while Institutions and Non-Institutions held 19.96% and 14.60% respectively.

The other top gainers on BSE “HC” space were Dr Reddys Lab up by 2.29%, Wochkhardt up by 2.07%, Biocon up by 1.32%, Cipla up by 1% and Lupin up by 0.89%, Ranbaxy Laboratories has recently commenced exports of Atorvastatin Calcium Oral Tablets to the US market, from its Mohali SEZ manufacturing facility, located in Punjab, India. The first consignment of Atorvastatin Tablets has been dispatched to the US market in March 2012. The supply of Atrovastatin tablets from India supplements the company’s current production from Ohm Laboratories Inc, USA.

Ranbaxy’s dosage facility at Mohali was approved by the US Food and Drug Administration (USFDA) in October 2011. Thereafter, in the first quarter of 2012, the company received approval from the USFDA to manufacture and market Atorvastatin 10mg, 20mg, 40mg and 80mg tablets. Earlier, international regulatory authorities such as the WHO-Geneva, National Medicine and Medical Devices Agency (NMMDA) - Romania, ANVISA- Brazil, TGA- Australia, Canada Health-Canada etc. had also approved the company's Mohali facility.

The new facility at Mohali will manufacture oral solid products for export to US, EU and other countries based on filings and after receiving the necessary approvals. It is equipped with the latest state-of-the-art technology, designed to meet global and local regulatory requirement and conforms to cGMP standards.

Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×